23 March 2016 - CADTH has received the following notice of a pending submission from Takeda for Entyvio (vedolizumab) for use by patients with Crohn's disease.

CADTH has already assessed vedolizumab for use by patients with ulcerative colitis.

For more details, go to: https://www.cadth.ca/vedolizumab-0